The 2014 National Action Plan for Adverse Drug Event Prevention of the Office of Disease Prevention and Health Promotion (ODPHP) identified that diabetes agents were one of the 3 highest priority drug classes.1 Within this class, insulin specifically requires tight control and close monitoring. Here, INS is linked to diabetes mellitus.